The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.
Thermo Fisher Scientific has officially opened its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, CA.1 The plant is intended to speed up both the development and commercialization of cell therapies, in an effort to both grow the life sciences space and improve patient outcomes.
As a result of the new facility, developers in the cell therapy space—including in biotech and biopharma—will be able to use Thermo Fisher’s product and tech experience to help design end-to-end manufacturing workflows.
"Our new Advanced Therapies Collaboration Center represents a significant milestone in our ongoing commitment to deliver solutions that address critical challenges in cell therapy development,” said Betty Woo, Thermo Fisher’s vice president of cell, gene, and advanced therapies. “By enabling access to our expertise and broad range of instrumentation, reagents, lab equipment and analytical solutions, we aim to help our customers overcome manufacturing hurdles and accelerate their path to commercialization. By fostering collaboration and innovation, the center is poised to play a pivotal role in helping to advance cell therapies, ultimately improving patient lives."
Assistance will come in various forms, including resources and support in transitioning to current good manufacturing practices (cGMP) manufacturing.
Perks of the ATxCC program include:
In other Thermo Fisher news, the company is also opening an “expanded footprint” of the aforementioned Carlsbad ATxCC in Philadelphia later this year, which joins current collaboration centers located in Singapore and Korea.
Reference
1. Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development. April 17, 2025. Accessed April 21, 2025. https://www.businesswire.com/news/home/20250417009744/en/Thermo-Fisher-Scientific-Opens-Advanced-Therapies-Collaboration-Center-in-Greater-San-Diego-to-Help-Accelerate-Cell-Therapy-Development
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds
July 18th 2025The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.